These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8445603)

  • 1. Gonadotropin releasing hormone agonist for chronic anovulatory uterine bleeding and severe anemia.
    Vercellini P; Fedele L; Maggi R; Vendola N; Bocciolone L; Colombo A
    J Reprod Med; 1993 Feb; 38(2):127-9. PubMed ID: 8445603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of goserelin depot, a gonadotropin-releasing hormone agonist, for the treatment of menorrhagia and severe anemia in women with leiomyomata uteri.
    Candiani GB; Vercellini P; Fedele L; Arcaini L; Bianchi S; Candiani M
    Acta Obstet Gynecol Scand; 1990; 69(5):413-5. PubMed ID: 2148663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
    Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
    Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depot goserelin and danazol pre-treatment before rollerball endometrial ablation for menorrhagia.
    Fraser IS; Healy DL; Torode H; Song JY; Mamers P; Wilde F
    Obstet Gynecol; 1996 Apr; 87(4):544-50. PubMed ID: 8602306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin releasing hormone agonist treatment before hysterectomy for menorrhagia and uterine leiomyomas.
    Vercellini P; Bocciolone L; Colombo A; Vendola N; Meschia M; Bolis G
    Acta Obstet Gynecol Scand; 1993 Jul; 72(5):369-73. PubMed ID: 8392268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GnRH agonists before surgery for uterine leiomyomas. A review.
    Crosignani PG; Vercellini P; Meschìa M; Oldani S; Bramante T
    J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of GnRH agonists depot for the treatment of dysfunctional uterine bleeding.
    Colacurci N; De Placido G; Galasso M; Mollo A; Perino A; Cittadini E
    Acta Eur Fertil; 1991; 22(4):229-31. PubMed ID: 1844328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotropin releasing hormone agonist treatment for severe menorrhagia in patients with contraindications to surgery.
    Vercellini P; Ferrari A; D'Alberton A; Motta T; Maggi R; Molteni P
    Eur J Obstet Gynecol Reprod Biol; 1992 Jun; 45(1):70-2. PubMed ID: 1535604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].
    Imperato F; Perniola G; Mossa B; Marziani R; Perniola F; Stragapede B; Napolitano C
    Minerva Ginecol; 2002 Jun; 54(3):271-8. PubMed ID: 12063443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE; Anania C; Malinak R
    J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Levonorgestrel-releasing intrauterine system in the treatment of dysfunctional uterine bleeding: A French multicenter study].
    Yazbeck C; Omnes S; Vacher-Lavenu MC; Madelenat P
    Gynecol Obstet Fertil; 2006 Oct; 34(10):906-13. PubMed ID: 16987684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The use of ferritin in 40 patients with iron deficiency of various degrees caused by gynecologic disorders].
    Bottino G; Menna C; Giarratana L; Marini C; Viberti G
    Minerva Ginecol; 1990 Jun; 42(6):275-6. PubMed ID: 2381559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of endometrial hyperplasia with Goserelin depot, an LH-RH analog].
    Pozzi M; Castagnola D; Cherubini F
    Minerva Ginecol; 1993 May; 45(5):251-4. PubMed ID: 8351064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Add-back therapy for long-term use in dysfunctional uterine bleeding and uterine fibroids.
    Thomas EJ
    Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():18-21. PubMed ID: 8916983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
    Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
    J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.
    Regidor PA; Regidor M; Schmidt M; Ruwe B; Lübben G; Förtig P; Kienle E; Schindler AE
    Gynecol Endocrinol; 2001 Jun; 15(3):202-9. PubMed ID: 11447732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate.
    Meirow D; Rabinovici J; Katz D; Or R; Shufaro Y; Ben-Yehuda D
    Cancer; 2006 Oct; 107(7):1634-41. PubMed ID: 16944540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of dysfunctional metrorrhagia with GnRH analogs].
    Zanella B; Bertelli E; Guerra S; Lenzi B; Mari MC
    Minerva Ginecol; 1992 Oct; 44(10):521-3. PubMed ID: 1461555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
    Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K
    Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects on the male endocrine system of long-term treatment with gonadotropin-releasing hormone agonists and estrogens in male-to-female transsexuals.
    Mueller A; Binder H; Cupisti S; Hoffmann I; Beckmann MW; Dittrich R
    Horm Metab Res; 2006 Mar; 38(3):183-7. PubMed ID: 16673210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.